Biotechnology Company Showcases OLC Bioequivalence Data

Unicycive Therapeutics, Inc., a clinical-stage biotechnology firm dedicated to improving the lives of patients with kidney disease, recently made strides in showcasing its innovative capabilities at the National Kidney Foundation (NKF) Spring Clinical Meeting. The company's lead product candidate, oxylanthanum carbonate (OLC), took center stage as promising bioequivalence data was presented, underscoring Unicycive’s commitment to advancing kidney disease treatment. $Unicycive Therapeutics(UNCY.US)$